Filana Therapeutics, Inc.
Income Statement
| Line Item | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|
| Revenue | $41.1M | $10.9M | $11.5M | $16.8M | $20.6M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $4.9M | $7.6M | $8.3M | $15.7M | $21.1M |
| SG&A Expense | $4.8M | $7.2M | $6.7M | $14.8M | $6.3M |
| Operating Income | $31.4M | $-3.9M | $-3.5M | $-13.7M | $-6.8M |
| Operating Margin | 76.3% | -35.8% | -30.6% | -81.5% | -32.8% |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $31.5M | $-3.4M | $-2.6M | $-12.0M | $-5.0M |
| Income Tax Expense | $-73.0K | $0 | $0 | — | $-1.5M |
| Net Income | $31.5M | $-3.4M | $-2.6M | $-12.0M | $-3.5M |
| Net Margin | 76.7% | -31.6% | -22.8% | -71.5% | -16.9% |
| EPS (Basic) | $0.70 | $-0.08 | $-0.06 | $-0.28 | $-0.08 |
| EPS (Diluted) | $0.70 | $-0.08 | $-0.06 | $-0.28 | $-0.08 |
| Shares Outstanding (Basic) | 45.0M | 44.8M | 44.2M | 42.9M | — |
| Shares Outstanding (Diluted) | 45.2M | 44.8M | 44.2M | 42.9M | — |
| Dividends Per Share | — | — | — | — | — |